Trial Profile
A Multicenter, Randomized, Double-Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral-Naive Hiv-Infected Patients With Ccr5-Tropic Hiv-1
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Darunavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms MODERN
- Sponsors ViiV Healthcare
- 05 Feb 2016 Results published in the AIDS
- 22 Jul 2014 Results published in the Media Release.
- 01 Nov 2013 Primary endpoint has not been met. (Virological response rate at week 48)